1. Autologous endothelial progenitor cell therapy improves right ventricular function in a model of chronic thromboembolic pulmonary hypertension.
- Author
-
Loisel F, Provost B, Guihaire J, Boulate D, Arouche N, Amsallem M, Arthur-Ataam J, Decante B, Dorfmüller P, Fadel E, Uzan G, and Mercier O
- Subjects
- Animals, Animals, Newborn, Arterial Pressure, Cells, Cultured, Disease Models, Animal, Pulmonary Arterial Hypertension etiology, Pulmonary Arterial Hypertension physiopathology, Pulmonary Embolism physiopathology, Recovery of Function, Sus scrofa, Time Factors, Transplantation, Autologous, Ventricular Dysfunction, Right etiology, Ventricular Dysfunction, Right physiopathology, Endothelial Progenitor Cells transplantation, Neovascularization, Physiologic, Pulmonary Arterial Hypertension surgery, Pulmonary Embolism complications, Stem Cell Transplantation, Ventricular Dysfunction, Right prevention & control, Ventricular Function, Right, Ventricular Remodeling
- Abstract
Background: Right ventricular (RV) failure is the main prognostic factor in pulmonary hypertension, and ventricular capillary density (CD) has been reported to be a marker of RV maladaptive remodeling and failure. Our aim was to determine whether right intracoronary endothelial progenitor cell (EPC) infusion can improve RV function and CD in a piglet model of chronic thromboembolic pulmonary hypertension (CTEPH)., Methods: We compared 3 groups: sham (n = 5), CTEPH (n = 6), and CTEPH with EPC infusion (CTEPH+EPC; n = 5). After EPC isolation from CTEPH+EPC piglet peripheral blood samples at 3 weeks, the CTEPH and sham groups underwent right intracoronary infusion of saline, and the CTEPH+EPC group received EPCs at 6 weeks. RV function, pulmonary hemodynamics, and myocardial morphometry were investigated in the animals at 10 weeks., Results: After EPC administration, the RV fractional area change increased from 32.75% (interquartile range [IQR], 29.5%-36.5%) to 39% (IQR, 37.25%-46.50%; P = .030). The CTEPH+EPC piglets had reduced cardiomyocyte surface areas (from 298.3 μm
2 [IQR, 277.4-335.3 μm2 ] to 234.6 μm2 (IQR, 211.1-264.7 μm2 ; P = .017), and increased CD31 expression (from 3.12 [IQR, 1.27-5.09] to 7.14 [IQR, 5.56-8.41; P = .017). EPCs were found in the RV free wall at 4 and 24 hours after injection but not 4 weeks later., Conclusions: Intracoronary infusion of EPC improved RV function and CD in a piglet model of CTEPH. This novel cell-based therapy might represent a promising RV-targeted treatment in patients with pulmonary hypertension., (Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF